Karen Prange Sells 3,000 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Karen Prange sold 3,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the completion of the sale, the director owned 26,373 shares in the company, valued at approximately $755,586.45. The trade was a 10.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

AtriCure Stock Performance

Shares of ATRC opened at $28.29 on Friday. The firm has a market cap of $1.43 billion, a PE ratio of -282.90 and a beta of 1.28. The stock’s fifty day moving average price is $28.62 and its two-hundred day moving average price is $33.64. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.29 and a quick ratio of 3.18. AtriCure, Inc. has a 1 year low of $25.52 and a 1 year high of $43.18.

Hedge Funds Weigh In On AtriCure

Several hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. grew its position in shares of AtriCure by 6.5% in the third quarter. PNC Financial Services Group Inc. now owns 6,188 shares of the medical device company’s stock valued at $218,000 after purchasing an additional 380 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares in the last quarter. Scotia Capital Inc. grew its position in shares of AtriCure by 1.2% in the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after purchasing an additional 457 shares in the last quarter. First Bank & Trust grew its position in shares of AtriCure by 6.0% in the fourth quarter. First Bank & Trust now owns 8,805 shares of the medical device company’s stock valued at $348,000 after purchasing an additional 495 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd grew its position in AtriCure by 197.1% during the third quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock worth $29,000 after buying an additional 538 shares in the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ATRC has been the topic of several research reports. Wall Street Zen lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Citigroup restated an “outperform” rating on shares of AtriCure in a research note on Wednesday, February 18th. BTIG Research restated a “buy” rating and issued a $54.00 target price on shares of AtriCure in a research note on Wednesday, February 18th. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 6th. Finally, Freedom Capital upgraded AtriCure to a “strong-buy” rating in a research report on Wednesday, April 1st. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.71.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.